A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation | Fontana, Marianna, Thomas A. Treibel, Ana Martinez-Naharro, Stefania Rosmini, Raymond Y. Kwong, Julian D. Gillmore, Philip N. Hawkins, and James C. Moon. 2017. “A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid.” BMC Medical Imaging 17 (1): 3. doi:10.1186/s12880-016-0173-5. http://dx.doi.org/10.1186/s12880-016-0173-5. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1186/s12880-016-0173-5 |
| Citable link | http://nrs.harvard.edu/urn-3:HUL.InstRepos:30371080 |
| Terms of Use | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
CASE REPORT

A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid

Marianna Fontana¹,², Thomas A. Treibel²,³, Ana Martinez-Naharro¹, Stefania Rosmini³, Raymond Y. Kwong⁴, Julian D. Gillmore¹, Philip N. Hawkins¹ and James C. Moon²,³*

Abstract

Background: Cardiac amyloidosis is a progressive but underdiagnosed and underappreciated cause of heart failure. In the last few years, cardiovascular magnetic resonance (CMR) has become the gold standard for non invasive diagnosis of cardiac amyloidosis with the characteristic subendocardial late gadolinium enhancement.

Case presentation: We describe a case of a patient who, in the process of aligning protocols for a trial between different centers, had a paired study with two different contrast agents, Dotarem® and MultiHance®. MultiHance® surprisingly failed to demonstrate the characteristic imaging pattern, showing only non specific late gadolinium enhancement at the inferior right ventricular insertion point and different myocardial extracellular volume fraction compared to the one obtained with Dotarem®. MultiHance® is used by many centres, because its partial blood protein binding is a strength for MR angiography, but late gadolinium enhancement, particularly non-ischemic, appears to be compromised.

Conclusions: This case report suggests that contrast agents should be selected with caution, especially with new therapies lining up for amyloid and CMR being used as exploratory end point in clinical trials.

Keywords: Case report, Amyloidosis, CMR, Contrast

Background

In the last decade, cardiovascular magnetic resonance (CMR) has grown dramatically and in amyloidosis has become the gold standard for non invasive diagnosis of cardiac involvement with the characteristic subendocardial late gadolinium enhancement (LGE) [1]. The number of new referrals for cardiac amyloidosis has significantly increased in the last few years, with the diagnosis being based on CMR and the characteristic LGE. New contrast agents favoured for their high relaxivity related to blood protein binding, [2] have become available but no one has ever tested the diagnostic performance of these new agents in infiltrative disease.

Case presentation

A 77-year old man presented with breathlessness and weight loss. Endoscopy and duodenal biopsy showed amyloid deposits, subtyped as transthyretin type (TTR). Investigations excluded a plasma cell dyscrasia, and showed atrial fibrillation on ECG (Fig. 1), and moderately increased wall thickness with moderate to severe diastolic dysfunction on echocardiography (Fig. 2, videos available as Additional files 1 and 2). TTR gene sequencing showed no mutation so the diagnosis was that of wild-type ATTR amyloidosis (senile systemic amyloidosis). Cardiac involvement, though likely, was not unequivocal as age/hypertension can confound.

* Correspondence: j.moon@ucl.ac.uk
²Institute of Cardiovascular Science, University College London, London, UK
³Barts Heart Centre, West Smithfield, London EC1A 7BE, UK
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Technetium-labelled bone scintigraphy and CMR were performed. Scintigraphy demonstrated grade 2 myocardial uptake, highly specific for cardiac amyloidosis. Cine CMR imaging supported the echocardiographic and scintigraphy findings. Tissue characterization showed clear amyloidosis with elevated native myocardial T1 (ShMOLLI, 1072 ms, normal 960 ms+/−30 ms) and, after contrast (Gadoterate meglumine, 0.1 mmol/kg, gadolinium-DOTA, Dotarem® Guerbet S.A. France), abnormal gadolinium kinetics on TI scout (nulling of the myocardium before the blood) and diffuse biventricular subendocardial LGE (Fig. 2) [1]. The extracellular volume fraction (ECV) at 15 min was 0.53.

Two weeks later, the CMR was repeated (same scanner and team with no changes in the patient regarding treatment or disease status) within the screening tests of a clinical trial, this time with a different contrast agent, gadobenate dimeglumine (0.1 mmol/kg, gadolinium-BOPTA, MultiHance®, Bracco, Milan, Italy). The cines and native T1 findings were the same (Fig. 3). The LGE however was markedly different – the subendocardial LGE so characteristic of amyloidosis was not visible, even with phase-sensitive inversion recovery (PSIR). There was just non-specific right ventricle insertion point LGE (Fig. 4). The ECV at 15 min obtained using Gd-BOPTA (MultiHance®) was now lower – 0.45 compared to 0.53 with gadolinium-DOTA (Dotarem®) (same acquisition time after contrast administration). This difference is higher than the expected variability of the technique. Prior publications demonstrate the ECV to
be stable to a standard deviation of 0.02 (0.03 for amyloid); [3] here a 0.08 difference with contrast agent is recorded.

Discussion

Gd-BOPTA (MultiHance®) is an ionic linear chelate favoured for its high relaxivity related to blood protein binding, [2] which also makes it a partially “intra-vascular” contrast agent. Here, paired scanning performed serendipitously for a clinical trial failed to demonstrate the characteristic pattern of myocardial amyloidosis, and performed poorly compared to gadoterate meglumine. MultiHance® is widely used for CMR. This effect was unexpected – but theoretical concerns had been raised for ECV mapping with protein bound contrast agents [4]. Due to difference in relaxivity between the contrast agents, some Authors proposed the use of a lower dose of Gd-BOPTA for reaching similar T1 and ECV values. In this case the same dose was used for both contrasts and this could explain in part the differences observed. In this case, the use of MultiHance® did not affect the diagnosis, but reporting the MultiHance® CMR in isolation without the previous work-up by the National Amyloid Centre could have conceivably led to a misdiagnosis.

Conclusion

We suggest that protein bound agents for interstitial enhancement of non-ischaemic cardiomyopathy (myocardium, ECV measurement) should be used with caution whilst further work is undertaken as the diagnostic performance may not be the same as non-protein bound variants.
Additional files

Additional file 1: Video 1. Echocardiogram: apical four chamber view. (AVI 5448 kb)
Additional file 2: Video 2. Echocardiogram: parasternal long axis view. (AVI 5765 kb)

Abbreviations
CMR: Cardiovascular magnetic resonance; ECG: Electrocardiogram; ECV: Extracellular volume; Gd: Gadolinium; LGE: Late gadolinium enhancement; PSIR: Phase Sensitive Inversion Recovery; ShMOLLI: Shortened Modified Look-Locker Inversion recovery; TTR: Transthyretin type

Acknowledgments
Not applicable.

Funding
No funding.

Availability of data and materials
If asked, I will provide or fully cooperate in obtaining and providing the original data on which the manuscript is based so the editors or their designates can examine it.

Authors’ contributions
MF and JCM have made substantial contributions to conception and design of the case, have been involved in drafting the manuscript and revising it critically for important intellectual content and have given final approval of the version to be published. TAT, AMN, RYK, JDG and PNH have made substantial contributions to conception and design of the case, have been involved in revising the manuscript critically for important intellectual content and have given final approval of the version to be published. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
Not applicable.

Author details
1National Amyloidosis Centre, University College London, Royal Free Hospital, London, UK. 2Institute of Cardiovascular Science, University College London, London, UK. 3Barts Heart Centre, West Smithfield, London EC1A 7BE, UK. 4Non-Invasive Cardiac Imaging, Cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

Received: 13 July 2016 Accepted: 21 December 2016
Published online: 07 January 2017

References
1. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.
2. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, Schick F. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41(3):213–21.
3. Fontana M, White SK, Banyersad SM, Sado DM, Maestrini V, Flett AS, Piechnik SK, Neubauer S, Roberts N, Moon JC. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLL1 versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2012;14:88.
4. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.